Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Sep 24, 2024
The amyotrophic lateral sclerosis treatment landscape is stringent and includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpool therapy, and others. The approved drugs for amyotrophic lateral sclerosis treatment include RILUZOLE, RADICAVA, TIGLUTIK, EXSERVAN, ...
Read More...
Sep 24, 2024
DelveInsight forecasts that with the launch of 15+ emerging therapies alongside existing treatments, the ALS treatment market is anticipated to surpass USD 4 billion across the 7MM by 2034. Currently, there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. As per ou...
Read More...
Sep 24, 2024
Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a rare, progressive, and fatal neuromuscular disease characterized by degeneration of upper and lower motor neurons. While it is associated with a mortality rate of 50% within 30 months of Amyotrophic Lateral Sclerosis symptoms onset, there is still no ...
Read More...
Feb 28, 2023
Sage Therapeutics Receives EU Orphan Drug Designation for Huntington's Disease Treatment Candidate Sage Therapeutics declared the European Medicines Agency granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington's disease. SAGE-718 is developing as a potential oral therapy for cognitive disor...
Read More...
Nov 15, 2022
Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper